Comparing NewAmsterdam Pharma (NASDAQ:NAMS) & Cyclerion Therapeutics (NASDAQ:CYCN)

NewAmsterdam Pharma (NASDAQ:NAMS) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Risk & Volatility

NewAmsterdam Pharma has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

Profitability

This table compares NewAmsterdam Pharma and Cyclerion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Cyclerion Therapeutics	N/A	-55.32%	-48.35%

Institutional & Insider Ownership

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares NewAmsterdam Pharma and Cyclerion Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$45.56 million	42.11	-$176.94 million	($2.60)	-6.72
Cyclerion Therapeutics	$2.00 million	4.08	-$5.26 million	($1.22)	-2.47

Cyclerion Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for NewAmsterdam Pharma and Cyclerion Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	6	0	3.00
Cyclerion Therapeutics	0	0	0	0	0.00

NewAmsterdam Pharma currently has a consensus price target of $43.33, indicating a potential upside of 148.04%. Given NewAmsterdam Pharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Cyclerion Therapeutics.

Summary

NewAmsterdam Pharma beats Cyclerion Therapeutics on 8 of the 13 factors compared between the two stocks.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.